{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:14:58Z","timestamp":1781478898393,"version":"3.54.1"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.smim.2020.101394","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T07:40:15Z","timestamp":1586158815000},"page":"101394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention"],"prefix":"10.1016","volume":"47","author":[{"given":"Camille","family":"Jacqueline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera J.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2020.101394_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101394_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-010-0968-0","article-title":"2011: the immune hallmarks of cancer","volume":"60","author":"Cavallo","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101394_bib0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0030","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101394_bib0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coi.2016.01.002","article-title":"Cancer immunoprevention","volume":"39","author":"Finn","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0045","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.smim.2020.101394_bib0050","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-17-0112","article-title":"Human tumor antigens yesterday, today, and tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0055","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1172\/JCI99538","article-title":"Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101394_bib0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.smim.2020.101394_bib0065","first-page":"261","article-title":"Overview of oncofetal antigens in cancer","volume":"13","author":"Wepsic","year":"1983","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.smim.2020.101394_bib0070","first-page":"2984","article-title":"CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients","volume":"55","author":"Qin","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0075","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carbone","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0080","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1073\/pnas.0500090102","article-title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens","volume":"102","author":"Lennerz","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2020.101394_bib0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2326-6066.CIR-16-0264","article-title":"Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity","volume":"5","author":"Zhang","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ccr.2010.11.011","article-title":"Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression","volume":"19","author":"DuPage","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.smim.2020.101394_bib0095","first-page":"2354","article-title":"Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas","volume":"57","author":"Nollau","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0100","series-title":"Adv. Exp. Med. Biol.","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-94-017-7215-0_7","article-title":"Prostate specifi c antigen as a tumor marker in prostate cancer: biochemical and clinical aspects","author":"Salman","year":"2015"},{"key":"10.1016\/j.smim.2020.101394_bib0105","first-page":"2143","article-title":"Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas","volume":"150","author":"Chi","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.smim.2020.101394_bib0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.onc.1201597","article-title":"Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to Chromosome 11q13","volume":"16","author":"Watson","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.smim.2020.101394_bib0115","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","article-title":"Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression","volume":"154","author":"Kawakami","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002371-200205000-00008","article-title":"Frequency of MART-1\/MelanA and gp100\/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes","volume":"25","author":"Seiter","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0125","series-title":"Adv. Immunol.","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-2776(04)82006-6","article-title":"MUC1 immunobiology: from discovery to clinical applications","author":"Vlad","year":"2004"},{"key":"10.1016\/j.smim.2020.101394_bib0130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1084\/jem.194.9.1313","article-title":"Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by t cells","volume":"194","author":"Kao","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0304-3835(02)00709-7","article-title":"Telomerase as tumor marker","volume":"194","author":"Hiyama","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.smim.2020.101394_bib0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood-2002-08-2554","article-title":"Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells","volume":"102","author":"Schmidt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101394_bib0145","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101394_bib0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K","article-title":"Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide","volume":"87","author":"Lewis","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0160","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.190.5.705","article-title":"High frequencies of naive Melan-A\/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals","volume":"190","author":"Pittet","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ijc.1361","article-title":"Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-\u03b3-elispot assay","volume":"93","author":"Griffioen","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0170","doi-asserted-by":"crossref","first-page":"14010","DOI":"10.1073\/pnas.0903225106","article-title":"Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer","volume":"106","author":"a Vella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2020.101394_bib0175","volume":"1","author":"Dhodapkar","year":"2000"},{"key":"10.1016\/j.smim.2020.101394_bib0180","volume":"1","author":"Valmori","year":"2001"},{"key":"10.1016\/j.smim.2020.101394_bib0185","first-page":"1193","article-title":"Mumps and ovarian cancer: moder interpretation of an historic association","volume":"21","author":"Cramer","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.smim.2020.101394_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10549-016-3801-4","article-title":"Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer","volume":"157","author":"Tabuchi","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.smim.2020.101394_bib0195","series-title":"Circulating Antibodies to Carcinoembryonic Antigen Related to Improved Recurrence-Free Survival of Patients with Colorectal Carcinoma","author":"Wu","year":"2011"},{"key":"10.1016\/j.smim.2020.101394_bib0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.smim.2020.101394_bib0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.coi.2011.01.002","article-title":"Epidemiological perspective on immune-surveillance in cancer","volume":"23","author":"Cramer","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00872","article-title":"Defining natural antibodies","volume":"8","author":"Holodick","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2013.00004","article-title":"Fundamental roles of the innate-like repertoire of natural antibodies in immune homeostasis","volume":"4","author":"Vas","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0220","series-title":"Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies","author":"Ochsenbein","year":"1999"},{"key":"10.1016\/j.smim.2020.101394_bib0225","first-page":"927","article-title":"The \u201cearly birds\u201d: natural IgM antibodies and immune surveillance","volume":"20","author":"Vollmers","year":"2005","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.smim.2020.101394_bib0230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.nbt.2009.03.016","article-title":"Natural antibodies and cancer","volume":"25","author":"Vollmers","year":"2009","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.smim.2020.101394_bib0235","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/labinvest.3780322","article-title":"A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody","volume":"81","author":"Hensel","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.smim.2020.101394_bib0240","first-page":"2541","article-title":"Characterization of glycosylphosphatidylinositol-linked molecule CD55\/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis","volume":"58","author":"Hensel","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1084\/jem.20021459","article-title":"Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development","volume":"197","author":"Hayakawa","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0250","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.4049\/jimmunol.147.12.4343","article-title":"Predominance of the prototypic T15 anti-phosphorylcholine junctional sequence in neonatal pre-B cells","volume":"147","author":"Feeney","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0255","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.4049\/jimmunol.1402771","article-title":"Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera","volume":"194","author":"Madi","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0260","series-title":"B-1 Cells Secrete Antibodies With Anti-Tumor Properties","author":"Rodriguez-Zhurbenko","year":"1950"},{"key":"10.1016\/j.smim.2020.101394_bib0265","series-title":"PAM-1, A Natural Human IgM Antibody as New Tool for Detection of Breast and Prostate Precursors","author":"Br\u00e4ndlein","year":"2004"},{"key":"10.1016\/j.smim.2020.101394_bib0270","series-title":"Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial Cancer Cells in Humans","author":"Br\u00e4ndlein","year":"2003"},{"key":"10.1016\/j.smim.2020.101394_bib0275","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ol.2016.5427","article-title":"Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer","volume":"13","author":"D\u00edaz-Zaragoza","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.smim.2020.101394_bib0280","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0285","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI14452","article-title":"Autoantibodies as predictors of disease","volume":"108","author":"Leslie","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101394_bib0290","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.4049\/jimmunol.176.8.5084","article-title":"Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in graves\u2019 disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways","volume":"176","author":"Gilbert","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0295","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0300","first-page":"210","article-title":"Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus, genomics","volume":"13","author":"Zhu","year":"2015","journal-title":"Proteomics Bioinform."},{"key":"10.1016\/j.smim.2020.101394_bib0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.smim.2020.101394_bib0310","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.21269","article-title":"Antigen microarray profiling of autoantibodies in rheumatoid arthritis","volume":"52","author":"Hueber","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2020.101394_bib0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/bjc.2016.369","article-title":"A protein fragment derived from DNA-topoisomerase i as a novel tumour-associated antigen for the detection of early stage carcinoma","volume":"115","author":"Yie","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0320","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3181","article-title":"Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer","volume":"14","author":"McGovern","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0325","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaut.2008.08.008","article-title":"Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices","volume":"31","author":"Szekanecz","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.smim.2020.101394_bib0330","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/BOR.0000000000000202","article-title":"Malignancies in systemic lupus erythematosus: a 2015 update","volume":"27","author":"Goobie","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.smim.2020.101394_bib0335","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101394_bib0340","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2020.101394_bib0345","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12885-015-1385-8","article-title":"Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis","volume":"15","author":"Fern\u00e1ndez Madrid","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0350","first-page":"2147","article-title":"Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations","volume":"4","author":"Ralhan","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0355","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/827827","article-title":"Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens","volume":"2014","author":"Dai","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0360","series-title":"T Cell-Dependent Antibody Responses Against Aberrantly Expressed Cyclin B1 Protein in Patients With Cancer and Premalignant Disease","author":"Suzuki","year":"2005"},{"key":"10.1016\/j.smim.2020.101394_bib0365","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-016-1838-1","article-title":"Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas","volume":"65","author":"Beatty","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0370","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1084\/jem.20072016","article-title":"Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness","volume":"205","author":"Willimsky","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0375","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101394_bib0380","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20031787","article-title":"Premalignant lesions as targets for cancer vaccines","volume":"198","author":"Finn","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF01630717","article-title":"Common infections in the history of cancer patients and controls","volume":"117","author":"Abel","year":"1991","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0390","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/ijc.28205","article-title":"Childhood infectious diseases and risk of leukaemia in an adult population","volume":"133","author":"Parodi","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0395","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00008390-199910000-00011","article-title":"Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer","volume":"9","author":"K\u00f6lmel","year":"1999","journal-title":"Melanoma Res."},{"key":"10.1016\/j.smim.2020.101394_bib0400","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0959-8049(03)00625-7","article-title":"Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study","volume":"39","author":"Krone","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0405","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1055-9965.EPI-05-0035","article-title":"Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer","volume":"14","author":"Cramer","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.smim.2020.101394_bib0410","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1055-9965.EPI-10-0068","article-title":"Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the nurses\u2019 health studies","volume":"19","author":"Pinheiro","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.smim.2020.101394_bib0415","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/2326-6066.CIR-13-0125","article-title":"Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor associated antigens : a new view of cancer immunosurveillance","volume":"2","author":"Iheagwara","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0420","first-page":"1280","article-title":"Development and preclinical evaluation of a Bacillus Calmette-Gu\u00e9rin-MUC1-based novel breast cancer vaccine","volume":"63","author":"Chung","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0425","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/1940-6207.CAPR-09-0194","article-title":"Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer Lessens colonic inflammation and prevents progression to colitis-associated colon cancer","volume":"3","author":"Beatty","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0430","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/onci.18950","article-title":"Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen","volume":"1","author":"Beatty","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101394_bib0435","first-page":"130","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"100","author":"Kimura","year":"2012","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.smim.2020.101394_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep31740","article-title":"Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential","volume":"6","author":"Lohmueller","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2020.101394_bib0445","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/2326-6066.CIR-14-0110","article-title":"Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic","volume":"2","author":"Finn","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101394_bib0450","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tibs.2014.11.001","article-title":"How pathogens use linear motifs to perturb host cell networks","volume":"40","author":"Via","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.smim.2020.101394_bib0455","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2015.00594","article-title":"Interaction of intestinal microorganisms with the human host in the framework of autoimmune diseases","volume":"6","author":"S\u00e1nchez","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0460","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/683489","article-title":"A possible link between infection with burkholderia bacteria and systemic lupus erythematosus based on epitope mimicry","volume":"2008","author":"Zhang","year":"2008","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0465","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm.1874","article-title":"Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis","volume":"14","author":"Kain","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0470","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cell.2016.03.001","article-title":"Microbiome and anticancer immunosurveillance","volume":"165","author":"Zitvogel","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101394_bib0475","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0480","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/1078-0432.CCR-07-1909","article-title":"A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6","volume":"13","author":"Vujanovic","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0485","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.4049\/jimmunol.169.10.5696","article-title":"Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive melan-A-specific CTL","volume":"169","author":"Rubio-Godoy","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0490","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1217","article-title":"Microbial ecology perturbation in human IgA deficiency","volume":"10","author":"Fadlallah","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0495","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan6619","article-title":"Natural polyreactive IgA antibodies coat the intestinal microbiota","volume":"358","author":"Bunker","year":"2017","journal-title":"Science (80-.)"},{"key":"10.1016\/j.smim.2020.101394_bib0500","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1476-4598-9-293","article-title":"Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1\u03b1 and HIF-2\u03b1 target genes","volume":"9","author":"Chun","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0505","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101394_bib0510","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","article-title":"The gut microbiota influences anticancer immunosurveillance and general health","volume":"15","author":"Routy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0515","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101394_bib0520","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.it.2008.12.004","article-title":"Linking allergy to autoimmune disease","volume":"30","author":"Valenta","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0525","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mai.2000.108312","article-title":"Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart","volume":"106","author":"Linneberg","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0530","article-title":"IgE, IgG4 and IgG response to tissue-specific and environmental antigens in patients affected by cancer","volume":"66","author":"Zennaro","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.smim.2020.101394_bib0535","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1002\/ijc.21752","article-title":"An overview of the association between allergy and cancer","volume":"118","author":"Turner","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0540","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000338994","article-title":"Relationship between allergy and cancer: an overview","volume":"159","author":"Rittmeyer","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0545","doi-asserted-by":"crossref","DOI":"10.1111\/cea.12178","article-title":"Epidemiological associations of allergy, IgE and cancer","author":"Josephs","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.smim.2020.101394_bib0550","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdv231","article-title":"IgE and risk of cancer in 37 747 individuals from the general population","volume":"26","author":"Helby","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0555","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1055-9965.EPI-18-1330","article-title":"Allergies and asthma in relation to cancer risk","volume":"28","author":"Kantor","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.smim.2020.101394_bib0560","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1154250","article-title":"Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival","volume":"5","author":"Wulaningsih","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101394_bib0565","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1158\/1078-0432.CCR-06-2819","article-title":"Polyclonal immunoglobulin e levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma","volume":"13","author":"Matta","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100044","article-title":"AllergoOncology: high innate IgE levels are decisive for the survival of cancer-bearing mice","volume":"12","author":"Singer","year":"2019","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.smim.2020.101394_bib0575","doi-asserted-by":"crossref","DOI":"10.1111\/cea.12178","article-title":"Epidemiological associations of allergy, IgE and cancer","volume":"43","author":"Josephs","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.smim.2020.101394_bib0580","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/592850","article-title":"Allergies: their role in cancer prevention","volume":"83","author":"Sherman","year":"2008","journal-title":"Q. Rev. Biol."},{"key":"10.1016\/j.smim.2020.101394_bib0585","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/0008-5472.CAN-16-1829","article-title":"Anti-folate receptor-\u03b1 IgE but not IgG recruits macrophages to attack tumors via TNF\u03b1\/MCP-1 signaling","volume":"77","author":"Josephs","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0590","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00262-012-1299-0","article-title":"Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1","volume":"61","author":"Teo","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0595","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00262-011-1150-z","article-title":"Targeting HER2\/neu with a fully human IgE to harness the allergic reaction against cancer cells","volume":"61","author":"Daniels","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0600","volume":"1","author":"Reali","year":"2001"},{"key":"10.1016\/j.smim.2020.101394_bib0605","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/eji.200323185","article-title":"Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells","volume":"33","author":"Karagiannis","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0610","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1158\/0008-5472.CAN-06-3758","article-title":"Active induction of tumor-specific IgE antibodies by oral mimotope vaccination","volume":"67","author":"Riemer","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0615","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2020.101394_bib0620","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0625","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0630","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101394_bib0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2016.05.003","article-title":"A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas","volume":"63","author":"Fiedler","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.smim.2020.101394_bib0640","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00262-008-0605-3","article-title":"Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study","volume":"58","author":"Schuetz","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.smim.2020.101394_bib0645","first-page":"1149","article-title":"CAR t cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"1","author":"Ferrone","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2020.101394_bib0650","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.2733","article-title":"MUC1 as a target for CAR\u2010T therapy in head and neck squamous cell carinoma","volume":"9","author":"Mei","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.smim.2020.101394_bib0655","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101394_bib0660","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR t cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101394_bib0665","first-page":"1549","article-title":"The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells","volume":"42","author":"Shen","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.smim.2020.101394_bib0670","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","article-title":"HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy\u2013resistant human melanoma in IL2 transgenic NOD\/SCID IL2 receptor knockout mice","volume":"79","author":"Forsberg","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2020.101394_bib0675","series-title":"Clin. Res. (Excluding Clin. Trials)","article-title":"Abstract LB-147: administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas","author":"Navai","year":"2019"},{"key":"10.1016\/j.smim.2020.101394_bib0680","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1040216","article-title":"T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma","volume":"5","author":"Singh","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101394_bib0685","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1211218","article-title":"Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome","volume":"5","author":"Wang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101394_bib0690","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s13238-017-0472-9","article-title":"Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells","volume":"8","author":"Jiang","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.smim.2020.101394_bib0695","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:18:58Z","timestamp":1760915938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":139,"alternative-id":["S1044532320300105"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101394","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101394"}}